Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06858579

PHASE3

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Sponsor: Dianthus Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

256

Start Date

2025-02-10

Completion Date

2030-12-31

Last Updated

2026-10-28

Healthy Volunteers

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

DRUG

Claseprubart

IV Infusion

DRUG

Claseprubart

SC injection

DRUG

Placebo

SC injection

Inclusion Criteria: 1. Must have given written informed consent before any study-related activities are carried out. 2. Weight range between 40 kilograms (kg) and 120 kg. 3. Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel. 4. CIDP Disease Activity Status (CDAS) score ≥ 3 at screening. 5. Must be neurologically stable. 6. Must have an INCAT score between 2 and 9 inclusive. 7. Must fulfill one of the following treatment conditions for CIDP: 1. Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin \[IVIg\] or subcutaneous immunoglobulin \[SCIg\]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids. 2. Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil. 3. Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and/or oral corticosteroids (defined as no clinically meaningful improvement after a period of a minimum of 12 weeks, which may include both active treatment and observation to assess response), or who at any time were unable to tolerate these treatments, experienced adverse effects, or have documented contraindications. 4. Treatment naïve with no history of prior treatment for CIDP. 8. Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability. 9. Female participants must be of nonchildbearing potential or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception. 10. Male participants must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception or be surgically sterile for at least 90 days prior to Screening. Exclusion Criteria: 1. Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP. 2. Known evidence of central demyelination or known history of myelopathy. 3. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could have a potential impact on safety/efficacy or study procedures. 4. Any other condition, including mental illness or prior therapy that would make the participant unsuitable for this study. 5. Known complement deficiency or history of positive titer for anti-C1 antibodies. 6. Diagnosis of systemic lupus erythematosus (SLE) or family history of SLE (defined as a parent, sibling, or child). 7. Participants with an autoimmune disease affecting joints, muscle or nervous system. 8. Any coexisting or overlapping condition, which may interfere with outcome assessments, such as severe diabetic neuropathy, fibromyalgia, inflammatory arthritis or osteoarthritis affecting the hands and feet. 9. Prior history of N. meningitidis infection. 10. History of active malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone. 11. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.

Locations (201)

Clinical Study Site

Birmingham, Alabama, United States

Clinical Study Site

Phoenix, Arizona, United States

Clinical Study Site

Scottsdale, Arizona, United States

Clinical Study Site

Los Angeles, California, United States

Clinical Study Site

San Francisco, California, United States

Clinical Study Site

San Francisco, California, United States

Cinical Study Site

New Haven, Connecticut, United States

Clinical Study Site

Washington D.C., District of Columbia, United States

Clinical Study Site

Maitland, Florida, United States

Clinical Study Site

Tampa, Florida, United States

Clinical Study Site

Honolulu, Hawaii, United States

Clinical Study Site

Chicago, Illinois, United States

Clinical Study Site

Edwardsville, Illinois, United States

Clinical Study Site

Indianapolis, Indiana, United States

Clinical Study Site

Kansas City, Kansas, United States

Clinical Study Site

Burlington, Massachusetts, United States

Clinical Study Site

East Lansing, Michigan, United States

Clinical Study Site

Omaha, Nebraska, United States

Cinical Study Site

Lebanon, New Hampshire, United States

Clinical Study Site

New York, New York, United States

Clinical Study Site

New York, New York, United States

Clinical Study Site

Cincinnati, Ohio, United States

Clinical Study Site

Columbus, Ohio, United States

Clinical Study Site

Portland, Oregon, United States

Cinical Study Site

Nashville, Tennessee, United States

Clinical Study Site

Dallas, Texas, United States

Clinical Study Site

Denton, Texas, United States

Cinical Study Site

Houston, Texas, United States

Texas Locations

Houston, Texas, United States

Clinical Study Site

Round Rock, Texas, United States

Clinical Study Site

Sugar Land, Texas, United States

Clinical Study Site

Seattle, Washington, United States

Cinical Study Site

Buenos Aires, Buenos Aires, Argentina

Cinical Study Site

Rosario, Santa Fe Province, Argentina

Cinical Study Site #3

Buenos Aires, Argentina

Cinical Study Site #4

Buenos Aires, Argentina

Cinical Study Site

Buenos Aires, Argentina

Clinical Study Site #2

Buenos Aires, Argentina

Clinical Study Site

Buenos Aires, Argentina

Cinical Study Site #2

San Miguel de Tucumán, Argentina

Clinical Study Site

San Miguel de Tucumán, Argentina

Cinical Study Site

Liverpool, New South Wales, Australia

Clinical Study Site

Randwick, New South Wales, Australia

Cinical Study Site

Saint Leonards, New South Wales, Australia

Cinical Study Site

Sydney, New South Wales, Australia

Cinical Study Site

Southport, Queensland, Australia

Clinical Study Site

Melbourne, Victoria, Australia

Cinical Study Site

Anderlecht, Brussels Capital, Belgium

Cinical Study Site

Brussels, Belgium

Cinical Study Site

Rio de Janeiro, Rio de Janeiro, Brazil

Clinical Study Site

Campinas, São Paulo, Brazil

Cinical Study Site

Belo Horizonte, Brazil

Cinical Study Site

Natal, Brazil

Cinical Study Site

Porto Alegre, Brazil

Cinical Study Site

Salvador, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

Sofia, Bulgaria

Clinical Study Site

Sofia, Bulgaria

Clinical Study Site

Hefei, Anhui, China

Clinical Study Site

Guangzhou, Guangdong, China

Clinical Study Site

Changsha, Hu'Nan, China

Clinical Study Site

Changsha, Hu'Nan, China

Clinical Study Site

Chifeng, Inner Mongolia, China

Clinical Study Site

Suzhou, Jiangsu, China

Clinical Study Site

Beijing, China

Clinical Study Site

Beijing, China

Clinical Study Site

Chengdu, China

Clinical Study Site

Fujian, China

Clinical Study Site

Guangdong, China

Clinical Study Site

Guangzhou, China

Clinical Study Site

Jilin City, China

Clinical Study Site

Shanghai, China

Clinical Study Site

Shanghai, China

Clinical Study Site

Sichuan, China

Clinical Study Site

Taiyuan, China

Clinical Study Site

Wuhan, China

Cinical Study Site

Medellín, Antioquia, Colombia

Cinical Study Site

Antioquia, Colombia

Cinical Study Site

Medellín, Colombia

Cinical Study Site

Osijek, Croatia

Clinical Study Site

Aarhus, Denmark

Clinical Study Site

Copenhagen, Denmark

Cinical Study Site

Ulm, Eswatini

Clinical Study Site

Bordeaux, France

Cinical Study Site

Brest, France

Clinical Study Site

Bron, France

Clinical Study Site

Clermont-Ferrand, France

Clinical Study Site

Libourne, France

Clinical Study Site

Marseille, France

Clinical Study Site

Nice, France

Clinical Study Site

Paris, France

Clinical Study Site

Paris, France

Clinical Study Site

Strasbourg, France

Cinical Study Site

Tours, France

Clinical Study Site

Tours, France

Clinical Study Site

Tbilisi, Georgia

Cinical Study Site

München, Bavaria, Germany

Clinical Study Site

Sande, Lower Saxony, Germany

And 101 more locations on ClinicalTrials.gov

Clinical Research Directory

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (201)